Trial Profile
A Double Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2014
Price :
$35
*
At a glance
- Drugs OMO-1 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen-Cilag
- 11 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2014 Planned End Date changed from 1 May 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 25 Jun 2014 Planned primary completion date changed from 1 May 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.